Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder.
Hirokawa
Makoto
M
Kawabata
Yoshinari
Y
Fujishima
Naohito
N
Yoshioka
Tomoko
T
Sawada
Ken-ichi
K
D000328:Adult; D000741:Anemia, Aplastic / Q000097:blood / Q000150:complications / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D016026:Bone Marrow Transplantation; D003587:Cytomegalovirus; D020031:Epstein-Barr Virus Infections / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D004854:Herpesvirus 4, Human / Q000502:physiology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008232:Lymphoproliferative Disorders / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D011859:Radiography; D000069283:Rituximab; D013997:Time Factors; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab